# US 2015/0105274 A1 · Methods for the Characterisation of Interaction Sites on Target Proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105274 A1
- Document ID: US20150105274A1
- Status: Published application
- Kind: A1
- Application number: 14/377,809
- Filed: 2013-02-07
- Published: 2015-04-16
- Earliest claimed: 2012-02-10
- Assignees: Phylogica Limited; Cambridge Enterprise Limited
- Applicants: Phylogica Limited; Cambridge Enterprise Limited
- Inventors: Paul Watt; Bryn Hardwick; Grahame McKenzie; Ashok Venkitaraman
- Web page: https://patentgrep.com/patent/US20150105274A1

## CPC

- G01N 33/6845: {Methods of identifying protein-protein interactions in protein mixtures}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/195: from bacteria
- C12N 15/1079: {Screening libraries by altering the phenotype or phenotypic trait of the host (reporter assays C12N15/1086)}
- G01N 33/5041: {involving analysis of members of signalling pathways}
- G01N 33/6842: {Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins}
- G16B 15/00: ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
- G16B 15/30: Drug targeting using structural data; Docking or binding prediction
- G16B 35/00: ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
- G16B 35/20: Screening of libraries
- G16C 20/60: In silico combinatorial chemistry
- G01N 2500/10: involving cells
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16C: COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE

## Abstract

The present invention relates to improved and integrated methods for the characterisation of an interaction site on a target protein that modulates the phenotype of a mammalian cell, such as a phenotype other than death and/or reduced growth. Such methods of the present invention include those to identify a target protein modulates such a phenotype of a mammalian cell, and optionally to characterise an interaction site on said target protein. Such identification and characterisation methods are useful in the development of research tools and/or therapeutics, such protein/peptide or small molecule therapeutics. Accordingly, the present invention also relates to methods of: identification of a ligand, such as a small molecule ligand, that binds to such a target protein; and identification a compound being a candidate modulator of said phenotype of a mammalian cell. The invention further relates to peptides or proteins, or fragments, variants and/or derivatives thereof) comprising certain amino acid sequences, nucleic acids encoding such peptides or proteins and uses of such peptides or proteins or of such nucleic acids.

## Claims

### Claim 1

A method of characterising an interaction site on a target protein, wherein the target protein modulates the phenotype of a mammalian cell other than death and/or reduced growth, said method comprising the steps:
exposing a population of in-vitro cultured mammalian cells capable of displaying said phenotype to a library of Phylomers;
identifying a cell in the population which displays an alteration in said phenotype following said exposure;
identifying a Phylomer that alters said phenotype of the cell;
providing the identified Phylomer;
identifying a cellular protein which binds to said provided Phylomer, said cellular protein being a target protein which modulates said phenotype of the mammalian cell;
providing said target protein;
providing a population of Phylomers which bind to said target protein;
empirically determining the binding configuration of at least one Phylomer within said population to said target protein; and
identifying: (i) locations of binding energy; and/or (ii) the orientation of at least one side chain of said Phylomer that interacts with said protein target, in either case by analysis of said binding configuration,
thereby characterising the interaction site on said target protein.

### Claim 2 (depends on 1)

The method according to claim 1 wherein the phenotype of a mammalian cell is:
one associated with a cell signalling pathway, preferably an activated cell signalling pathway; and/or
one selected from the list consisting of: viability, senescence, differentiation, migration, invasion, chemotaxis, apoptosis, immunological anergy, surface marker expression, progress through the cell cycle, transcriptional activity, protein expression, glycosylation, resistance to infection, permeability and reporter-gene activity

### Claim 3 (depends on 1)

The method according to claim 1: (i) said library of Phylomers comprises a plurality of separate and addressable Phylomers; or (ii) said library of Phylomers is expressed from a plurality of separate and addressable nucleic acids that encode Phylomers.

### Claim 4 (depends on 3)

The method according to claim 3 wherein:
(i) said plurality of separate and addressable Phylomers are exposed to said population of mammalian cells arranged in an array-format; or (ii) said plurality of separate and addressable nucleic acids are expressed in said population of mammalian cells arranged in an array-format; and/or
said cell which displays an alteration in said phenotype following said exposure or said expression is identified from said population of mammalian cells arranged in an array-format;
wherein, in each case, said array-format is a plate-based assay system.

### Claim 5 (depends on 1)

The method according to claim 1: (i) said library of Phylomers comprises a pooled plurality of Phylomers; or (ii) said library of Phylomers is expressed from a pooled plurality of nucleic acids that encode Phylomers.

### Claim at position 6

-7. (canceled)

### Claim 8 (depends on 1)

The method according to claim 1:
(i) said library of Phylomers comprises 3×104 or more, such as 1×106 or more, different amino acid sequences; (ii) or said library of Phylomers is expressed from a plurality of nucleic acids comprising 3×104 or more, such as 1×106 or more, different nucleic acid sequences that encode Phylomers; and/or
(a) said library of Phylomers comprises 3×104 or more, such as 1×106 or more, different Phylomers; or (b) said library of Phylomers is expressed from a plurality of nucleic acids that encode 3×104 or more, such as 1×106 or more, different Phylomers.

### Claim 9 (depends on 1)

The method according to claim 1 comprising isolating, from said population of mammalian cells, said cell which displays said alteration in phenotype following exposure to said library of Phylomers.

### Claim at position 9

-11. (canceled)

### Claim 12 (depends on 1)

The method according to claim 1 wherein said provided Phylomer is provided as part of a fusion protein that comprises the Phylomer and an affinity tag.

### Claim 13 (depends on 1)

The method according to claim 1 comprising, prior to identification of said cellular protein, isolating a cellular protein which binds to said provided Phylomer.

### Claim at position 12

-15. (canceled)

### Claim 16 (depends on 1)

The method according to claim 1 wherein said cellular protein is identified by mass spectrometry or by protein-microarray analysis with said provided Phylomer.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The method according to claim 1 wherein said provided target protein is provided in isolated form.

### Claim at position 16

-20. (canceled)

### Claim 21 (depends on 1)

The method according to claim 1 wherein, prior to its provision, said population of Phylomers is identified by screening a library Phylomers, or of nucleic acids that encode Phylomers, for binding of said encoded Phylomers to said target protein.

### Claim at position 18

-30. (canceled)

### Claim 31 (depends on 1)

The method according to claim 1 wherein said interaction site is further characterised by characterising the three dimensional structure of said interaction site by analysis of said binding configuration;
wherein said three dimensional structure is characterised using in silico methods.

### Claim 32 (depends on 31)

A method of identifying a ligand which binds to a target protein, wherein the target protein modulates the phenotype of a mammalian cell other than death and/or reduced growth, said method comprising the step:
identifying, using in silico methods, the structure of a ligand which is dockable to a three dimensional structure of an interaction site of said target protein, wherein said three dimensional structure is determined by a method of claim 31.

### Claim at position 21

-35. (canceled)

### Claim 36

A method of identifying a target protein which modulates the phenotype of a mammalian cell, other than death and/or reduced growth, said method comprising the steps:
exposing a population of in-vitro cultured mammalian cells capable of displaying said phenotype to a library of Phylomers;
identifying a cell in the population which displays an alteration in said phenotype following said exposure;
identifying a Phylomer that alters said phenotype of the cell;
providing the identified Phylomer; and
identifying a cellular protein which binds to said provided Phylomer,
said cellular protein being a target protein which modulates said phenotype of the mammalian cell.

### Claim 37 (depends on 36)

The method according to claim 36 further comprising the steps:
providing said target protein and said provided Phylomer; and
determining the effect of a test compound on the binding of said Phylomer to said target protein,
wherein a test compound which modulates the degree of binding of said Phylomer to said target protein is a candidate modulator of said phenotype of the mammalian cell.

### Claim 38

A method of identifying a compound which is a candidate modulator of the phenotype of a mammalian cell, other than death and/or reduced growth, said method comprising the steps:
exposing a population of in-vitro cultured mammalian cells capable of displaying said phenotype to a library of Phylomers;
identifying a cell in the population which displays an alteration in said phenotype following said exposure;
identifying a Phylomer that alters said phenotype of the cell;
providing the identified Phylomer;
identifying a cellular protein which binds to said provided Phylomer, said cellular protein being a target protein which modulates said phenotype of the mammalian cell;
providing said target protein and said provided Phylomer; and
determining the effect of a test compound on the binding of said Phylomer to said target protein,
wherein a test compound which modulates the degree of binding of said Phylomer to said target protein is a candidate modulator of said phenotype of the mammalian cell.

### Claim 39

(canceled)

### Claim 40

A method of characterising an interaction site on a target protein which modulates the phenotype of a mammalian cell, other than death and/or reduced growth, said method comprising the steps:
providing said target protein;
providing a population of Phylomers which bind to said target protein;
empirically determining the binding configuration of at least one Phylomer within said population to said target protein; and
identifying: (i) locations of binding energy; and/or (ii) the orientation of at least one side chain of said Phylomer that interacts with said protein target, in either case by analysis of said binding configuration,
thereby characterising the interaction site on said target protein.

### Claim at position 27

-42. (canceled)

### Claim 43

A method of identifying a Phylomer which modulates the phenotype of a mammalian cell, other than death and/or reduced growth, said method comprising the steps:
exposing a population of in-vitro cultured mammalian cells capable of displaying said phenotype to a library of Phylomers;
identifying a cell in the population which displays an alteration in said phenotype following said exposure; and
identifying a Phylomer that alters said phenotype of the cell,
said Phylomer being one which modulates said phenotype of the mammalian cell.

### Claim 44

A peptide or protein comprising the amino acid sequence of a peptide selected from the list consisting or: 4G9, 6F6, 6G8, 10B11, 25C3, 44B2 and 48E6, or a fragment, variant and/or derivative of said peptide or protein;
wherein, said peptide or protein, and/or a fragment, variant or derivative thereof: (i) modulates a the phenotype of a mammalian cell, other than death and/or reduced growth; and/or (ii) binds to a target protein that modulates a phenotype of a mammalian cell, other than death and/or reduced growth.

### Claim at position 30

-48. (canceled)
